Ipo Impath Predictive Oncology Trademark Details

Ipo Impath Predictive Oncology was registered on Tuesday, July 1, 2003 and is currently owned by Genzyme Corporation under the registration number 2731185 . This mark is dead with a status of Cancelled - Section 8. The last case file activity for this mark occured 14 years ago on Saturday, February 6, 2010, according to the United State Patent & Trademark Office
Word Mark Ipo Impath Predictive Oncology
Status Dead Registered 710 — Cancelled - Section 8

Current Owner

Genzyme Corporation of Cambridge, MA

View all trademarks for Genzyme Corporation
Other Trademarks for Genzyme Corporation

Previous Owners

Impath Inc. of New York, NY

View all trademarks for Impath Inc.
Other Trademarks for Impath Inc.
Serial Number 76226598
Registration Number 2731185
Status Date Saturday, February 6, 2010
Filing Date Saturday, February 6, 2010
Registration Date Tuesday, July 1, 2003
Attorney John J. Butler

Correspondent

Legal Department
Genzyme Corporation
15 Pleasant Street Connector
Framingham MA 01701-9322

Case File Statements

Disclaimer with Predetermined Text "Predictive Oncology"
Description of Mark The mark consists of the stylized letters "IPO".
Goods & Services Biopharmacogenomic services, namely research and development in targeted drug and diagnostic product discovery, drug development and diagnostic product and targeted therapies for others

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 2 — Sec. 8 – Entire Registration
Status Date Saturday, February 6, 2010
First Use Anywhere Saturday, September 30, 2000
First Use In Commerce Saturday, September 30, 2000
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.